Medical Developments International (MVP) investor relations material

Executive summary

• Achieved strong financial performance in FY 2026, with group revenue of AUD 42.6 million (or $42.6m), up 9% year-over-year, and significant progress in pain management and improved earnings in both core segments.

• Free cash flow reached AUD 4.2 million, up AUD 5.8 million from FY 2025, increasing cash balances to over AUD 21 million.

• Penthrox volume grew in all regions, with 18% growth in Europe and 28% in the Australian hospital segment.

• Pediatric label expansion for Penthrox in Europe, with approvals and launches in the UK and EU, and publication of a health economic study in Australia.

• Extension of PBS eligibility for Penthrox to nurse practitioners in Australia.

Financial highlights

• Group revenue: AUD 42.6 million, up 9% year-over-year.

• Pain management revenue up 21% to AUD 31.6 million, driven by higher volumes and pricing; respiratory segment revenue down 15% to AUD 10.9 million.

• EBIT improved to AUD 0.2 million, and NPAT increased to AUD 0.6 million.

• Free cash flow: AUD 4.2 million; operating cash flow: AUD 5.8 million.

• Cash at period end: AUD 21.4 million.

Outlook and guidance

• Expect higher in-market demand for Penthrox in FY 2027, supported by pediatric indication and health economic data.

• Respiratory segment demand expected to remain stable.

• No repeat of FY 2026 Penthrox inventory stocking benefits in FY 2027.

• Amortization expense of approx. AUD 1 million expected for European pediatric registration costs.

• Monitoring risks from Middle East supply chain disruptions and U.S. tariffs.